ReadingResearchRadarInvestment framework
Sign in / Sign up
← Back to reading
NewsMaterial2 min readDisconfirmAI Editorial

Shanghai AI Biotech Startup YuanShi Tech Completes ~300M RMB Pre-A Round, Claiming New Record for Domestic AI Virtual Cell Sector

YuanShi Tech secured a ~300 million RMB Pre-A round led by Legend Capital to build automated experimental platforms and iterate on general cell large models, highlighting strong investor interest in the AI virtual cell sector.

2026-11-19 14:02 GMT+8

Zhidongxi reported on November 19 that Shanghai-based AI biotech startup YuanShi Tech has completed a Pre-A funding round of nearly 300 million RMB. The round was led by Legend Capital, with participation from Huaxia Lingtou, JD-affiliated funds, CMC Capital, and others, while LightSource Capital served as the exclusive financial advisor. According to reports from PEdaily, China Merchants Capital, CDH VGC, and existing investors including Monolith, Sinovation Ventures, Daotong Investment, and Yanyuan Venture also participated or continued to add capital. This transaction claims to set a new record for single-round financing in the domestic AI Virtual Cell (AIVC) sector.

This marks YuanShi Tech's third announced funding round within one month. Founded in April 2026, the company primarily develops AI virtual cell models aimed at predicting cellular responses under various disease states, experimental conditions, and interventions. Previously, in October, the company completed Angel and Angel+ rounds totaling nearly 100 million RMB. The new funds are planned for accumulating cell intervention and response data, building automated experimental platforms, iterating on general cell large models, and expanding the R&D team.

YuanShi Tech's core technical approach involves constructing a "dry-wet closed loop" of "model prediction—experimental validation—data feedback—model update." Through this mechanism, the model identifies prediction shortcomings via experimental feedback, assists researchers in selecting the next round of experiments, and uses new results to supplement training data and improve predictions. The company describes this process as the application of Recursive Self-Improvement (RSI) in biological foundation models. Externally, YuanShi Tech has reached a strategic partnership with Yongsheng Intelligent, a subsidiary of MGI Tech, to co-build an automated experimental platform for virtual cells, aiming to reduce manual operation variances and accelerate data production.

Sign in / Sign up
ReadingResearchRadarInvestment framework

The founding team possesses strong academic backgrounds. Co-founder and CEO Wu Jiaqi holds a PhD in Systems Biology from Peking University and previously conducted postdoctoral research at Rockefeller University. Co-founder and CTO Dong Mingze graduated from Peking University's Yuanpei College with a bachelor's degree and earned a PhD in Computational Biology from Yale University, having worked at Stanford University and Anthropic. Dong announced his full-time joining on November 11; he contributed to the STACK model, which achieved zero-shot generalization across different cellular environments.

Sources

  • zhidx.com↗
  • news.pedaily.cn投资界↗
Continue researching →